The Lymphoid Molecular Profile detects mutations in key genes recurrently mutated in lymphoid malignancies. DNA sequence of targeted regions of the ABL1, ABL2, ALK, ARHGEF1, ARID1A, ARID2, ASXL1, ATM, B2M, BCL2, BCL6, BCOR, BIRC3, BRAF, BTK, CARD11, CCND1, CND2, CCND3, CD274, CD79A, CD79B, CDKN1B, CDKN2A, CDKN2B, CIITA, CREBBP, CRLF2, CSF1R, CTCF, CTNNB1, CXCR4, DDX3X, DIS3, DNMT3A, EBF1, EGR1, EP300, EPOR, ETV6, EZH2, FAM46C, FAS, FAT1, FBXW7, FGFR3, FOXO1, GATA3, GNA13, GNAI2, HIST1H1E, HRAS, ID3, IDH1, IDH2, IKBKB, IKZF1, IKZF3, IRAK4, ITPKB, JAK1, JAK2, JAK3, KLF2, KMT2D, KRAS, MALT1, MAP2K1, MAP3K14, MAPK1, MED12, MEF2B, MYC, MYCN, MYD88, NF1, NFKBIE, NOTCH1, NOTCH2, NOTCH3, NRAS, NT5C2, P2RY8, PDGFRB, PHF6, PIK3CA, PIK3CD, PIK3R1, PIM1, PLCG1, PLCG2, POT1, PPM1D, PRDM1, PRPS1, PTEN, PTPN11, RB1, REL, RHOA, RIPK1, RPS15, RUNX1, S1PR2, SAMHD1, SETD2, SF3B1, SGK1, SH2B3, SOCS1, SPEN, STAT3, STAT5B, STAT6, TBL1XR1, TCF3, TET2, TLR2, TNFAIP3, TNFRSF14, TP53, TRAF2, TRAF3, UBR5, WT1, XPO1, ZFHX4, and ZMYM3 genes is determined using next-generation sequencing (NGS) technology.
Note: This test is available to legacy Genoptix and New York clients only.
The Lymphoid Molecular Profile is intended as an aid in the diagnosis and subclassification of lymphoid neoplasms as well as to identify potential therapies based on the patient's unique molecular drivers. The profile includes analysis of genes known to be recurrently mutated in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Richter's syndrome (RS), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), hairy cell leukemia (HCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), double-hit lymphoma (DHL), and various T-cell neoplasms.
- Peripheral blood: 2-3 mL in EDTA (purple-top) tube.
- Bone marrow: 2-3 mL in EDTA (purple-top) tube.
- Tissue (Preferred): Two (2) formalin-fixed, paraffin-embedded tissue/ fine needle aspirate (FFPE/FNA) blocks containing tumor tissue from recent surgery or biopsy or sixteen (16) 2x5 µm sections with accompanying H&E slide.
- Acceptable Alternative: One (1) formalin-fixed, paraffin-embedded tissue/fine needle aspirate (FFPE/FNA) block containing tumor tissue from recent surgery or biopsy or eight (8) 2×5 µm sections with accompanying H&E slide.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. DO NOT FREEZE.